Hospital for Special Surgery, 535 East 70th Street, New York, NY, 10021, USA.
Department of Orthopaedic Surgery, University of Virginia, Charlottesville, VA, USA.
Knee Surg Sports Traumatol Arthrosc. 2023 Aug;31(8):3307-3315. doi: 10.1007/s00167-023-07373-4. Epub 2023 Mar 23.
To evaluate the 5-year rate of survival without undergoing arthroplasty or high tibial osteotomy (HTO) in subjects with mild-to-moderate medial compartment knee osteoarthritis (OA) who were treated with an implantable shock absorber (ISA) system.
Three prospective, sequential, multicenter, international, single-arm clinical trials were conducted comprising subjects who received an ISA for symptomatic medial knee OA after failing ≥ 6 months of conservative therapy. Study outcomes were analyzed cumulatively and by enrollment group when all subjects' follow-up data exceeded the 2-year threshold after ISA implantation. Primary outcome was survival rate without conversion to arthroplasty/HTO. Secondary outcomes were changes in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain and function scores after ISA implantation.
All 171 enrolled subjects (age 51 ± 9 years, body-mass index 28.5 ± 3.5 kg/m, 38% female; study knee Kellgren-Lawrence score 2.7 ± 0.9 points) were followed for a minimum of 2, and up to 5, years after device implantation. Overall, 90.6% (155/171) of subjects survived without requiring arthroplasty/HTO at last follow-up (mean 3.2 ± 1.6 years). The Kaplan-Meyer median 3- and 5-year survival-without-arthroplasty point estimates were 89.8% (95% CI 86.5‒95.7%) and 84.9% (95% CI 75.1‒91.1%), respectively. The median 3-year estimated survival rate for the most recent study (n = 81) was 97.3%. The mean WOMAC Pain score decreased 71% from baseline to last follow-up after ISA implantation, from 58 ± 13 to 16 ± 17 points (p < 0.0001). The Function score improved 69%, decreasing from 56 ± 18 to 17 ± 17 points (p < 0.0001).
In younger patients with mild-to-moderate symptomatic medial compartment knee OA, implantation of the ISA device resulted in a 5-year survival rate of 85% from undergoing arthroplasty or HTO. The ISA system may be an effective treatment option for working-age patients with medial knee OA who are not candidates for or do not desire more invasive surgical approaches.
II.
评估在接受可植入式减震器 (ISA) 系统治疗的轻至中度内侧间室膝骨关节炎 (OA) 患者中,5 年内无需进行关节置换或胫骨高位截骨术 (HTO) 的生存率。
进行了三项前瞻性、连续、多中心、国际、单臂临床试验,纳入了在接受 ≥ 6 个月保守治疗后仍有症状的内侧膝关节 OA 并接受 ISA 治疗的患者。当所有患者的随访数据超过 ISA 植入后 2 年的阈值时,按入组组进行累积分析和分析。主要结局为无转换为关节置换/HTO 的生存率。次要结局为 ISA 植入后 Western Ontario 和 McMaster 大学骨关节炎指数 (WOMAC) 疼痛和功能评分的变化。
所有 171 名入组患者(年龄 51 ± 9 岁,体重指数 28.5 ± 3.5 kg/m²,38%为女性;研究侧膝关节 Kellgren-Lawrence 评分 2.7 ± 0.9 分)在 ISA 植入后至少 2 年,最长 5 年进行了随访。总体而言,在最后一次随访时,90.6%(155/171)的患者无需进行关节置换/HTO 即可存活(平均 3.2 ± 1.6 年)。Kaplan-Meier 中位数 3 年和 5 年无关节置换生存率点估计值分别为 89.8%(95%CI 86.5-95.7%)和 84.9%(95%CI 75.1-91.1%)。最近一项研究(n=81)的中位 3 年估计生存率为 97.3%。ISA 植入后,WOMAC 疼痛评分从基线平均降低 71%,从 58 ± 13 降至 16 ± 17 分(p<0.0001)。功能评分改善 69%,从 56 ± 18 降至 17 ± 17 分(p<0.0001)。
在患有轻至中度有症状的内侧间室膝骨关节炎的年轻患者中,ISA 装置植入后,5 年内无需进行关节置换或 HTO 的生存率为 85%。ISA 系统可能是内侧膝骨关节炎、不适合或不希望接受更具侵袭性手术方法的工作年龄患者的有效治疗选择。
II 级。